Antihypertensive Therapy Considering the Prevention of Vascular Aging

참고문헌 (42)

1. Isomaa B, "Cardiovascular morbidity and mortality associated with the metabolic syndrome", Diabetes Care, 24, pp.683~689 (2001)
2. Safar ME, "Metabolic syndrome and age-related progression of aortic stiffness", Journal of the American College of Cardiology, 47, pp.72~75 (2006)
3. Lewington S, "Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies", Lancet, 360, pp.1903~1913 (2002)
4. Chobanian AV, "The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report", JAMA, 289, pp.2560~2572 (2003)
5. Mancia G, "2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)", European Heart Journal, 28, pp.1462~1536 (2007)
6. Ogihara T, "The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009)", Hypertension Research, 32, pp.3~107 (2009)
7. Struthers AD, "Review of aldosteroneand angiotensin II-induced target organ damage and prevention", Cardiovascular Research, 61, pp.663~670 (2004)
8. Schmieder RE, "Renin-angiotensin system and cardiovascular risk", Lancet, 369, pp.1208~1219 (2007)
9. Kuller LH, "Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial", American Journal of Epidemiology, 144, pp.537~547 (1996)
10. Schillaci G, "C-reactive protein in hypertension: clinical significance and predictive value", Nutrition, Metabolism & Cardiovascular Diseases, 16, pp.500~508 (2006)
11. Hage FG, "C-reactive protein gene polymorphisms, C-reactive protein blood levels, and cardiovascular disease risk", American College of Cardiology Foundation, 50, pp.1115~1122 (2007)
12. Steinberg D, "Beyond cholesterol. Modifications of lowdensity lipoprotein that increase its atherogenicity", The New England Journal of Medicine, 320, pp.915~924 (1989)
13. Witztum JL, "Role of oxidized low density lipoprotein in atherogenesis", Journal of Clinical Investigation, 88, pp.1785~1792 (1991)
14. Mertens A, "Oxidized LDL and HDL: antagonists in atherothrombosis", FASEB Journal, 15, pp.2073~2084 (2001)
15. Nada T, "Clinical study with azelnidipine in patients with essential hypertension. Antiarteriosclerotic and cardiac hypertrophy-inhibitory effects and influence on autonomic nervous activity", Arzneimittelforschung, 57, pp.698~704 (2007)
16. Ohmura C, "Calcium channel blocker, azelnidipine, reduces lipid hydroperoxides in patients with type 2 diabetes independent of blood pressure", Endocrine Journal, 54, pp.805~811 (2007)
17. Remuzzi G, "The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease", Kidney International, pp.57~65 (2005)
18. Brewster UC, "The reninangiotensin-aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states", American Journal of the Medical Sciences, 326, pp.15~24 (2003)
19. London GM, "Arterial stiffness: pathophysiology and clinical impact", Clinical and Experimental Hypertension, 26, pp.689~699 (2004)
20. Matsui Y, "Reproducibility of arterial stiffness indices (pulse wave velocity and augmentation index) simultaneously assessed by automated pulse wave analysis and their associated risk factors in essential hypertensive patients", Hypertension Research, 27, pp.851~857 (2004)
21. Ito N, "Clinical usefulness and limitations of brachial-ankle pulse wave velocity in the evaluation of cardiovascular complications in hypertensive patients", Hypertension Research, 29, pp.989~995 (2006)
22. Takaki A, "Cardio-ankle vascular index is superior to brachial-ankle pulse wave velocity as an index of arterial stiffness", Hypertension Research, 31, pp.1347~1355 (2008)
23. Smith DH, "Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan", American Journal of Cardiovascular Drugs, 5, pp.41~50 (2005)
24. Go AS, "Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization", The New England Journal of Medicine, 351, pp.1296~1305 (2004)
25. Bakris GL, "Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group", American Journal of Kidney Diseases, 36, pp.646~661 (2000)
26. Campese VM, "Hypertension in renal parenchymal disease: why is it so resistant to treatment", Kidney International, 69, pp.967~973 (2006)
27. Bigazzi R, "Microal buminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension", Journal of Hypertension, 16, pp.1325~1333 (1998)
28. Jensen JS, "Arterial hypertension, microalbuminuria, and risk of ischemic heart disease", Hypertension, 35, pp.898~903 (2000)
29. Yuyun MF, "Microalbuminuria independently predicts all-cause and cardiovascular mortality in a British population: The European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study", International Journal of Epidemiology, 33, pp.189~198 (2004)
30. Klausen K, "Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes", Circulation, 110, pp.32~35 (2004)
31. Elliott WJ, "Is fixed combination therapy appropriate for initial hypertension treatment", Current Hypertension Reports, 4, pp.278~285 (2002)
32. Mori H, "Current status of antihypertensive prescription and associated blood pressure control in Japan", Hypertension Re, 29, pp.143~151 (2006)
33. Dahlof B, "Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial", Lancet, 366, pp.896~906 (2005)
34. Williams B, "Differential impact of blood pressurelowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study", Circulation, 113, pp.1213~1225 (2006)
35. Jamerson K, "Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients", The New England Journal of Medicine, 359, pp.2417~2428 (2008)
36. Bakris GL, "Renal outcomes with different fixeddose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial", Lancet, 375, pp.1173~1181 (2010)
37. Ishimitsu T, "Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension", Hypertension Research, 32, pp.962~968 (2009)
38. Lupo E, "In vitro antioxidant activity of calcium antagonists against LDL oxidation compared with alpha-tocopherol", Biochemical and Biophysical Research Communications, 203, pp.1803~1808 (1994)
39. Bakris GL, "Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study", Kidney International, 73, pp.1303~1309 (2008)
40. Ishimitsu T, "Combination of angiotensin II receptor antagonist with calcium channel blocker or diuretic as antihypertensive therapy for patients with chronic kidney disease", Clinical and Experimental Hypertension, 33, pp.366~372 (2011)
41. Messerli FH, "Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous", Annals of Internal Medicine, 144, pp.884~893 (2006)
42. Cooper-DeHoff RM, "Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease", JAMA, 304, pp.61~68 (2010)

관련 논문AI추천